Oracle growth initiative gives CROs access to innovative Clinical One platform to spur adoption and improve trial efficiencies
Although increased investment in pharmaceutical research and development is creating more opportunities for CROs, many are struggling to keep pace with competitive pressures, changing market requirements and a lack of skilled talent. To help CROs meet these challenges, Oracle introduced its CRO Growth Initiative in August 2022. The global program offers CROs no-obligation access to Oracle Clinical One, a leading eClinical platform, for non-production purposes. Through the program, CROs can evaluate, familiarize, train and enable their users with the technology and demonstrate the power of Clinical One to potential sponsors. Already, hundreds of CRO professionals have taken advantage of the program’s accelerator that provides go-to-market benefits, technical enablers and incentives all constructed to help them get trials up and running faster.
Clinical One is the only truly unified eClinical platform that harmonizes data, streamlines workflow and saves significant time from study start-up to study closeout. It enables stakeholders to have quick and easy access to the data needed to support critical decision-making, patient safety and study oversight. The platform integrates with legacy systems and wider application ecosystems; it can ingest any commonly used data source and format; and it can configure and scale for traditional, hybrid or fully decentralized trials.
“FHI Clinical chose Oracle’s Clinical One platform as our default clinical system because it is built the way we would have built for ourselves — single data source, unified platform, intuitive and cost-efficient,” said Rob King, Chief Operating Officer, FHI Clinical.
For more information, refer to this press release.
